Page:United States Statutes at Large Volume 121.djvu/941

 121 STAT. 920

Penalties.

dkrause on GSDDPC44 with PUBLAW

Deadline.

VerDate Aug 31 2005

13:52 Jan 23, 2009

PUBLIC LAW 110–85—SEPT. 27, 2007

have any bearing on the accuracy of the information in the entry.’. ‘‘(vi) COMPLIANCE SEARCHES.—The Director of NIH shall provide that the public may easily search the registry and results data bank for entries that include notices required under this subparagraph. ‘‘(6) LIMITATION ON DISCLOSURE OF CLINICAL TRIAL INFORMATION.— ‘‘(A) IN GENERAL.—Nothing in this subsection (or under section 552 of title 5, United States Code) shall require the Secretary to publicly disclose, by any means other than the registry and results data bank, information described in subparagraph (B). ‘‘(B) INFORMATION DESCRIBED.—Information described in this subparagraph is— ‘‘(i) information submitted to the Director of NIH under this subsection, or information of the same general nature as (or integrally associated with) the information so submitted; and ‘‘(ii) information not otherwise publicly available, including because it is protected from disclosure under section 552 of title 5, United States Code. ‘‘(7) AUTHORIZATION OF APPROPRIATIONS.—There are authorized to be appropriated to carry out this subsection $10,000,000 for each fiscal year.’’. (b) CONFORMING AMENDMENTS.— (1) PROHIBITED ACTS.—Section 301 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331) is amended by adding at the end the following: ‘‘(jj)(1) The failure to submit the certification required by section 402(j)(5)(B) of the Public Health Service Act, or knowingly submitting a false certification under such section. ‘‘(2) The failure to submit clinical trial information required under subsection (j) of section 402 of the Public Health Service Act. ‘‘(3) The submission of clinical trial information under subsection (j) of section 402 of the Public Health Service Act that is false or misleading in any particular under paragraph (5)(D) of such subsection (j).’’. (2) CIVIL MONEY PENALTIES.—Subsection (f) of section 303 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 333), as redesignated by section 226, is amended— (A) by redesignating paragraphs (3), (4), and (5) as paragraphs (5), (6), and (7), respectively; (B) by inserting after paragraph (2) the following: ‘‘(3)(A) Any person who violates section 301(jj) shall be subject to a civil monetary penalty of not more than $10,000 for all violations adjudicated in a single proceeding. ‘‘(B) If a violation of section 301(jj) is not corrected within the 30-day period following notification under section 402(j)(5)(C)(ii), the person shall, in addition to any penalty under subparagraph (A), be subject to a civil monetary penalty of not more than $10,000 for each day of the violation after such period until the violation is corrected.’’; (C) in paragraph (2)(C), by striking ‘‘paragraph (3)(A)’’ and inserting ‘‘paragraph (5)(A)’’;

Jkt 059194

PO 00001

Frm 00918

Fmt 6580

Sfmt 6581

M:\STATUTES\2007\59194PT1.001

APPS10

PsN: 59194PT1

�